## CITATION REPORT List of articles citing

Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults

DOI: 10.1097/ftd.ob013e3181684fa0 Therapeutic Drug Monitoring, 2008, 30, 320-32.

Source: https://exaly.com/paper-pdf/45030988/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
91	Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2008</b> , 327, 38-44	4.7	30
90	Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. <i>Journal of Clinical Psychopharmacology</i> , <b>2008</b> , 28, 432-40	1.7	53
89	Disposition of MDMA and metabolites in human sweat following controlled MDMA administration. <i>Clinical Chemistry</i> , <b>2009</b> , 55, 454-62	5.5	28
88	Involvement of inferior parietal lobules in prospective memory impairment during acute MDMA (ecstasy) intoxication: an event-related fMRI study. <i>Neuropsychopharmacology</i> , <b>2009</b> , 34, 1641-8	8.7	36
87	Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. <i>Journal of Analytical Toxicology</i> , <b>2009</b> , 33, 439-46	2.9	36
86	Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 2079-86	4	49
85	Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 2163-70	4	62
84	MDMA: on the translation from rodent to human dosing. <i>Psychopharmacology</i> , <b>2009</b> , 204, 375-8	4.7	46
83	Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 367-73	3.2	16
82	Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatum. <i>Neurotoxicity Research</i> , <b>2010</b> , 18, 200-9	4.3	5
81	Population pharmacokinetics of 3,4-methylenedioxymethamphetamine and main metabolites in rats. <i>Toxicological Sciences</i> , <b>2010</b> , 114, 38-47	4.4	5
80	RECENT DEVELOPMENT IN THE APPLICATIONS OF COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPH. <i>Journal of Liquid Chromatography and Related Technologies</i> , <b>2010</b> , 33, 1082-1115	1.3	18
79	Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. <i>Clinical Pharmacokinetics</i> , <b>2011</b> , 50, 319-29	6.2	24
78	Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse. <i>NeuroToxicology</i> , <b>2011</b> , 32, 823-7	4.4	16
77	High concentrations of MDMA ('ecstasy') and its metabolite MDA inhibit calcium influx and depolarization-evoked vesicular dopamine release in PC12 cells. <i>Neuropharmacology</i> , <b>2011</b> , 61, 202-8	5.5	19
76	Ecstasy use and suicidal behavior among adolescents: findings from a national survey. <i>Suicide and Life-Threatening Behavior</i> , <b>2011</b> , 41, 435-44	3.9	12
75	Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users. <i>Addiction</i> , <b>2011</b> , 106, 1293-300	4.6	45

74	Pharmacodynamic interactions between MDMA and concomitants in MDMA tablets on extracellular dopamine and serotonin in the rat brain. <i>European Journal of Pharmacology</i> , <b>2011</b> , 660, 318-25	5.3	11
73	(–́)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. <i>Journal of Analytical Toxicology</i> , <b>2011</b> , 35, 470-80	2.9	10
72	The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 439-52	4.6	363
71	Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2011</b> , 338, 310-7	4.7	10
7º	The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. <i>Biological Chemistry</i> , <b>2011</b> , 392, 103-15	4.5	56
69	Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 1748-56	5.5	22
68	Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT). <i>PLoS ONE</i> , <b>2012</b> , 7, e47599	3.7	40
67	Toxicity of amphetamines: an update. <i>Archives of Toxicology</i> , <b>2012</b> , 86, 1167-231	5.8	296
66	Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. <i>British Journal of Pharmacology</i> , <b>2012</b> , 166, 1523-36	8.6	49
65	Impairment based legislative limits for driving under the influence of non-alcohol drugs in Norway. <i>Forensic Science International</i> , <b>2012</b> , 219, 1-11	2.6	117
64	Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain. <i>European Journal of Pharmacology</i> , <b>2012</b> , 674, 337-44	5.3	22
63	Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents. <i>Analytical and Bioanalytical Chemistry</i> , <b>2012</b> , 402, 195-208	4.4	30
62	Driving on ice: impaired driving skills in current methamphetamine users. <i>Psychopharmacology</i> , <b>2013</b> , 225, 161-72	4.7	13
61	Neurotoxicity of "ecstasy" and its metabolites in human dopaminergic differentiated SH-SY5Y cells. <i>Toxicology Letters</i> , <b>2013</b> , 216, 159-70	4.4	31
60	Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. <i>European Journal of Pharmaceutical Sciences</i> , <b>2013</b> , 49, 57-64	5.1	9
59	Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. <i>Analytical and Bioanalytical Chemistry</i> , <b>2013</b> , 405, 4067-76	4.4	16
58	High incidence of mild hyponatraemia in females using ecstasy at a rave party. <i>Nephrology Dialysis Transplantation</i> , <b>2013</b> , 28, 2277-83	4.3	30
57	Single oral doses of (´-) 3,4-methylenedioxymethamphetamine ('Ecstasy') produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations. International Journal of Neuropsychopharmacology 2013, 16, 791-801	5.8	8

56	Behavioral effects and pharmacokinetics of (-)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) after intragastric administration to baboons. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2013</b> , 345, 342-53	4.7	5
55	The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 17, 527-40	5.8	50
54	Solid-Phase Extraction. <b>2014</b> , 1-8		
53	Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 7754-62	6.6	39
52	Effect of 3,4-methylenedioxymethamphetamine on the toxicokinetics and sedative effects of the drug of abuse, Ehydroxybutyric acid. <i>Journal of Pharmaceutical Sciences</i> , <b>2014</b> , 103, 3310-5	3.9	1
51	Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats. <i>British Journal of Pharmacology</i> , <b>2014</b> , 171, 83-91	8.6	29
50	Effects of MDMA on the Human Nervous System. <b>2014</b> , 475-497		3
49	Analytical interference of 4-hydroxy-3-methoxymethamphetamine with the measurement of plasma free normetanephrine by ultra-high pressure liquid chromatography-tandem mass spectrometry. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 1121-3	3.5	24
48	3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration. <i>Analytical and Bioanalytical Chemistry</i> , <b>2014</b> , 406, 587-99	4.4	19
47	Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 119-25	4	27
46	Baths salts, spice, and related designer drugs: the science behind the headlines. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 15150-8	6.6	111
45	Simultaneous analysis of amphetamine-type stimulants in plasma by solid-phase microextraction and gas chromatography-mass spectrometry. <i>Journal of Analytical Toxicology</i> , <b>2014</b> , 38, 432-7	2.9	9
44	An in vitro approach to assessing a potential drug interaction between MDMA (ecstasy) and caffeine. <i>Toxicology in Vitro</i> , <b>2014</b> , 28, 231-9	3.6	5
43	The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. <i>Frontiers in Human Neuroscience</i> , <b>2014</b> , 8, 204	3.3	128
42	Conduite automobile et amphEamines dans le sang Lases bibliographiques pour un consensus de la SociLfran lise de toxicologie analytique. <i>Toxicologie Analytique Et Clinique</i> , <b>2015</b> , 27, 142-152	0.4	1
41	Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 1864-71	4	16
40	Development and validation of an LC-MS/MS method after chiral derivatization for the simultaneous stereoselective determination of methylenedioxy-methamphetamine (MDMA) and its phase I and II metabolites in human blood plasma. <i>Drug Testing and Analysis</i> , <b>2015</b> , 7, 592-602	3.5	11
39	MDMA Impairs Response to Water Intake in Healthy Volunteers. <i>Advances in Pharmacological Sciences</i> , <b>2016</b> , 2016, 2175896	4.9	4

## (2020-2016)

38	Development of a high-speed MALDI-triple quadrupole mass spectrometric method for the determination of 3,4-methylenedioxymethamphetamine (MDMA) in oral fluid. <i>Drug Testing and Analysis</i> , <b>2016</b> , 8, 235-40	3.5	8
37	Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. <i>Addiction Biology</i> , <b>2016</b> , 21, 339-47	4.6	76
36	Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine. <i>Toxicology Letters</i> , <b>2016</b> , 243, 48-55	4.4	9
35	Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. <i>European Neuropsychopharmacology</i> , <b>2017</b> , 27, 232-238	1.2	28
34	Safety pharmacology of acute MDMA administration in healthy subjects. <i>Journal of Psychopharmacology</i> , <b>2017</b> , 31, 576-588	4.6	70
33	Altered Insula Connectivity under MDMA. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 2152-2162	8.7	18
32	Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 649-660	8.7	20
31	Key interindividual determinants in MDMA pharmacodynamics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 183-195	5.5	11
30	3,4-Methylenedioxymethamphetamine causes cytotoxicity on 661W cells through inducing macrophage polarization. <i>Cutaneous and Ocular Toxicology</i> , <b>2018</b> , 37, 143-150	1.8	2
29	The psychostimulant (´-)-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters. <i>Neuropharmacology</i> , <b>2018</b> , 138, 282-291	5.5	16
28	Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine. <i>ACS Chemical Neuroscience</i> , <b>2018</b> , 9, 2408-2427	5.7	27
27	Cognitive Effects of MDMA in Laboratory Animals: A Systematic Review Focusing on Dose. <i>Pharmacological Reviews</i> , <b>2019</b> , 71, 413-449	22.5	10
26	Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. <i>Journal of Psychoactive Drugs</i> , <b>2019</b> , 51, 108-117	3.6	8
25	In further defense of nonclinical abuse liability testing of biologics. <i>Regulatory Toxicology and Pharmacology</i> , <b>2019</b> , 101, 103-120	3.4	O
24	MDMA Increases Cooperation and Recruitment of Social Brain Areas When Playing Trustworthy Players in an Iterated Prisoner's Dilemma. <i>Journal of Neuroscience</i> , <b>2019</b> , 39, 307-320	6.6	15
23	Adverse pharmacokinetic interactions between illicit substances and clinical drugs. <i>Drug Metabolism Reviews</i> , <b>2020</b> , 52, 44-65	7	9
22	Treatment of a Complex Personality Disorder Using Repeated Doses of LSD-A Case Report on Significant Improvements in the Absence of Acute Drug Effects. <i>Frontiers in Psychiatry</i> , <b>2020</b> , 11, 573953	<b>3</b> 5	1
21	Consommation decstasy surdos Dropos d n cas mortel. <i>Toxicologie Analytique Et Clinique</i> , <b>2020</b> , 32, S23	0.4	

20	Consommation decstasy surdos II propos dun cas mortel. <i>Toxicologie Analytique Et Clinique</i> , <b>2020</b> , 32, 308-314	0.4	
19	Toxicological analysis of serious drug-related harm among electronic dance music festival attendees in New South Wales, Australia: A consecutive case series. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 213, 108070	4.9	4
18	Ecstasy (3,4-methylenedioxymethamphetamine): Cardiovascular effects and mechanisms. <i>European Journal of Pharmacology</i> , <b>2021</b> , 903, 174156	5.3	1
17	AmphEamines et dEivE. <b>2012</b> , 455-505		2
16	MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 602-8	3.2	16
15	Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study. <i>Intensive Care Medicine Experimental</i> , <b>2020</b> , 8, 21	3.7	9
14	MDMA impairs response to water intake in healthy volunteers.		
13	MDMA Ihopes and fears associated with therapeutic use in mental disorders. <i>Pharmacotherapy in Psychiatry and Neurology</i> , <b>2020</b> , 36, 187-204	0.1	
12	Amphetamines/Sympathomimetic Amines. <b>2020</b> , 449-466		
11	CytoSorb removes MDMA in vitro, but is it an effective therapy in vivo?. <i>Intensive Care Medicine Experimental</i> , <b>2020</b> , 8, 38	3.7	
10	Drug and MDMA Interactions Implications for Public Health. <b>2022</b> , 1-26		
9	MDMA and memory, addiction, and depression: dose-effect analysis <i>Psychopharmacology</i> , <b>2022</b> , 239, 935	4.7	5
8	Guide dinterprelation des concentrations salivaires des stupfiants, proposipar la SFTA. <i>Toxicologie Analytique Et Clinique</i> , <b>2022</b> ,	0.4	
7	Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review <i>Psychopharmacology</i> , <b>2022</b> , 1	4.7	1
6	Trust and Psychopharmaca:. <b>2021</b> , 338-368		
5	Neuromolecular Level of Trust. <b>2021</b> , 313-386		
4	Soumission chimique impliquant la MDMA : 🏻 propos dun cas inhabituel. <i>Toxicologie Analytique Et Clinique</i> , <b>2022</b> ,	0.4	
3	Drug and MDMA Interactions Implications for Public Health. <b>2022</b> , 2243-2268		O

Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans. **2022**, 23, 14636

The Usefulness of Metabolites in the Interpretation of Drug Test Results. 2017, 305-324

O

2